You are here: Home » PTI Stories » National » News
Business Standard

Zydus Cadila gets tentative nod from USFDA for diabetes drug

Press Trust of India  |  New Delhi 

has received tentative approval from the US health regulator to market tablets, indicated for treating diabetes, in the American market.

The company has received tentative approval from the Food and Drug Administration (USFDA) for tablets in strengths of 25 mg, 50 mg, and 100 mg, said in a BSE filing.

It said the drug will be produced at the group's formulations facility at SEZ, Ahmedabad.

The group has more than 217 approvals, and so far filed over 330 abbreviated new drug applications (ANDAs).

Shares of Cadila Healthcare, the listed entity of the group, were trading 0.59 per cent lower at Rs 418.30 per scrip on BSE.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Tue, September 11 2018. 12:30 IST